Risk of serious atrial fibrillation and stroke with use of bisphosphonates: Evidence from a meta-analysis

Chest

Volumn 144, Issue 4, 2013, Pages 1311-1322

  Sharma, Abhishek ^a   Chatterjee, Saurav ^c,d   Arbab Zadeh, Armin ^e   Goyal, Sandeep ^f   Lichstein, Edgar ^a   Ghosh, Joydeep ^b   Aikat, Shamik ^g  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885094953     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0675     Document Type: Article

References (47)

1. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: Department of Health and Human Services; 2004.
2. Advisory Group on Osteoporosis. Report. London, England: Department of Health; 1994.
3. Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18): 1809-1822.
4. Lyles KW, Colón-Emeric CS, Magaziner JS, et al; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357 (18): 1799-1809.
5. Woolf AD, Akesson K. Preventing fractures in elderly people. BMJ. 2003; 327 (7406): 89-95.
6. de Nijs RN, Jacobs JW, Lems WF, et al; STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006; 355 (7): 675-684.
7. Bone HG, Hosking D, Devogelaer JP, et al; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350 (12): 1189-1199.
8. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343 (9): 604-610.
9. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008; 149 (6): 404-415.
10. Hodgson SF, Watts NB, Bilezikian JP, et al; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 [published correction appears in Endocr Pract. 2004;10(1)90]. Endocr Pract. 2003; 9 (6): 544-564.
11. American College of Obstetricians and Gynecologists Women's Health Care Physicians. Osteoporosis. Obstet Gynecol. 2004; 104 (suppl 4): 66S - 76S.
12. Clinician's Guide to Prevention and Treatment of Osteoporo sis. Washington, DC: National Osteoporosis Foundation; 2008.
13. Bunch TJ, Anderson JL, May HT, et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol. 2009; 103 (6): 824-828.
14. Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009; 265 (5): 581-592.
15. Huang WF, Tsai YW, Wen YW, Hsiao FY, Kuo KN, Tsai CR. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause. 2010; 17 (1): 57-63.
16. Erichsen R, Christiansen CF, Frøslev T, Jacobsen J, Sørensen HT. Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study. Br J Cancer. 2011; 105 (7): 881-883.
17. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008; 168 (8): 826-831.
18. Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008; 336 (7648): 813-816.
19. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS ONE. 2009; 4 (3): e4720.
20. Levesque L, Blagojevec A, Etminan M, Brophy J. Oral bisphosphonates and the risk of atrial fibrillation in a cohort of older adults. Pharmacoepidemiol Drug Saf. 2009; 18(abstr): S114.
21. Wilkinson GS, Baillargeon J, Kuo YF, Freeman JL, Goodwin JS. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol. 2010; 28 (33): 4898-4905.
22. Sauty A, Pecherstorfer M, Zimmer-Roth I, et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone. 1996; 18 (2): 133-139.
23. van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 1999; 255 (2): 491-494.
24. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000; 373 (1): 231-241.
25. Thompson K, Dunford JE, Ebetino FH, Rogers MJ. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun. 2002; 290 (2): 869-873.
26. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogencontaining bisphosphonates. J Pharmacol Exp Ther. 2001; 296 (2): 235-242.
27. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature. 1995; 375(6527): 155-158.
28. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005; 139(1): 101-111.
29. Das H, Wang L, Kamath A, Bukowski JF. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood. 2001; 98 (5): 1616-1618.
30. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003; 108 (24): 3006-3010.
31. Ylitalo R, Kalliovalkama J, Wu X, et al. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol. 1998; 83 (3): 125-131.
32. Shimshi M, Abe E, Fisher EA, Zaidi M, Fallon JT. Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice. Biochem Biophys Res Commun. 2005; 328 (3): 790-793.
33. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007; 356 (18): 1895-1896.
34. Black DM, Cummings SR, Karpf DB, et al; Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996; 348 (9041): 1535-1541.
35. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280 (24): 2077-2082.
36. Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med. 2007; 357 (7): 712-713.
37. Lewiecki EM, Cooper C, Thompson E, Hartl F, Mehta D, Papapoulos SE. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract. 2010; 64 (6): 821-826.
38. Higgins JPT, Green S, eds. Cochrane Handbook for System atic Reviews of Interventions. Chichester, England: Wiley; 2008.
39. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012; 27 (2): 243-254.
40. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6 (7): e1000100.
41. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998; 52 (6): 377-384.
42. Kemeny-Suss N, Kasneci A, Rivas D, et al. Alendronate affects calcium dynamics in cardiomyocytes in vitro. Vascul Pharmacol. 2009; 51 (5-6): 350-358.
43. Haring G, Kralj E, Balažic J, Ermenc B. Diagnostic value of post-mortem examination of the cardiac conduction system. Forensic Science International Supplement Series. 2009; 1 (1): 72-75.
44. Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005; 20 (11): 1912-1920.
45. Ylitalo R. Bisphosphonates and atherosclerosis. Gen Pharmacol. 2000; 35 (6): 287-296.
46. Bhuriya R, Singh M, Molnar J, Arora R, Khosla S. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2010; 142 (3): 213-217.
47. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 2009; 32 (3): 219-228.